Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 29, 2021

Coronavirus company news summary – GSK and Vir submit EUA application to FDA for Covid-19 monoclonal antibody treatment – EMA recommends Celltrion’s regdanvimab for severe Covid-19

By Chris Lo

GSK and Vir Biotechnology have submitted an application for Emergency Use Authorization (EUA) with the US Food and Drug Administration (FDA) for use of investigational monoclonal antibody VIR-7831 (GSK4182136) in the treatment of adults and adolescents with mild symptoms of Covid-19. The two companies made the EUA submission based on the interim analysis of effectiveness and safety data from their Phase III COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial.

The European Medicines Agency (EMA) has advised EU member states to use Celltrion Group’s regdanvimab (CT-959) for patients with severe Covid-19, based on a positive opinion given by the agency’s Committee for Medicinal Products for Human Use (CHMP). Regdanvimab has demonstrated an ability to neutralise the SARS-CoV-2 wild-type virus, as well as prominent mutations such as the UK variant (B.1.17).

The Russian Direct Investment Fund (RDIF) has announced that the health ministry of Antigua and Barbuda has authorised the use of Sputnik V, the Russian-made Covid-19 vaccine. Sputnik V has now received authorisation for use in 57 countries across the world making it the second most approved coronavirus vaccine in terms of government approvals.

Related Companies

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU